Suboxone Recovery Centerof Arkansas · Fayetteville 479-856-1505

Home/Articles/News

The DEA's 2027 Opioid Quota: What It Means for Pain Patients in Northwest Arkansas

News

On November 10, the Drug Enforcement Administration published its proposed 2027 production limits for opioid pain medicines. These numbers decide how much oxycodone, hydrocodone and other strong opioids drug makers are allowed to produce for the whole country next year.

If you or someone in your family takes a prescription pain medicine, you may be wondering whether this means another round of shortages or cutoffs here in Northwest Arkansas. Here is what the notice actually says, what it does not say, and what I would want my own family to know.

What the DEA proposed for 2027

Every year the DEA sets an "aggregate production quota" for Schedule I and II drugs. It relies on the Food and Drug Administration to estimate how much medical use there will be. In this year's notice, the DEA quotes the FDA directly: medical use of Schedule II opioids is predicted to "decline on average 9.68 percent" in 2027.

The proposed quotas themselves are cut much less than that. When I compared the new numbers with the quotas the DEA set for 2026:

  • Oxycodone (for sale) drops from about 50.24 million grams to 49.83 million grams, a cut of about 0.8 percent.
  • Hydrocodone (for sale) drops from about 26.98 million grams to 26.84 million grams, a cut of about 0.5 percent.
  • Fentanyl and oxymorphone are down by tiny fractions of a percent, and morphine is unchanged.
  • Hydromorphone goes up. The DEA raised it this fall because of shortages of the injectable form used in hospitals.

Pain News Network calls these "minor cuts" and points out that the supply has been reduced every year for about a decade. The public can comment until December 10, 2026, and the final numbers come after that.

Will my pharmacy run out?

I can't promise what any one pharmacy will have on the shelf. Shortages can happen for reasons that have nothing to do with the quota, like manufacturing problems or a distributor's ordering limits. The DEA itself says it watches for drug shortages and wants patients with a real medical need to be able to get their medicine.

What I can tell you is that a cut of less than one percent is a small change at the national level. For most patients, the bigger risks are closer to home. A prescriber retires. A clinic closes. A dose gets lowered quickly. Or a pharmacy stops filling a prescription. Those are the moments when I see people get into trouble.

Why a sudden stop is the real danger

If your body has gotten used to an opioid, stopping all at once is not just uncomfortable. The FDA warned in 2019 that suddenly stopping or rapidly cutting opioid pain medicine has led to serious withdrawal, uncontrolled pain, psychological distress and suicide. The FDA also warned that some people in that spot turn to illicit opioids.

Here, that is especially dangerous. The DEA warns that fake pills made to look like real oxycodone or hydrocodone often contain fentanyl. A pill bought from a friend or off the street is not the same medicine your pharmacist handed you.

The CDC's opioid prescribing guideline says opioids should not be stopped abruptly unless there is a life-threatening issue, and that doses should not be cut fast from high levels. If your prescriber is changing your dose, it is fair to ask for a slow, planned taper. I wrote more about that in what to do if your pain pills were cut off.

Where Suboxone fits, and where it does not

This quota notice covers Schedule I and II drugs. Buprenorphine, the main medicine in Suboxone, is a Schedule III drug, so it is not part of these production numbers.

I want to be careful here. Suboxone is not a replacement pain prescription, and I don't put someone on it just because their pain medicine ran short. It is a treatment for opioid use disorder. That is when opioids have taken more control than you want. Maybe you run out early, take more than prescribed, buy pills, or can't stop even though it is hurting you.

If that sounds like you or someone you love, the CDC says clinicians should offer or arrange medication for opioid use disorder. The CDC also says detox alone is not recommended because it raises the risk of relapse and overdose death. The National Institute on Drug Abuse says medications such as buprenorphine lower the risk of overdose and death.

If you have been using pills that might contain fentanyl, starting buprenorphine has to be timed right. I explain why in starting Suboxone after fentanyl. That is one reason your first dose with me is taken in person.

What Northwest Arkansas families can do now

  • If you take pain medicine, don't stop it on your own. Talk with the doctor who prescribes it first.
  • If your pharmacy can't fill a prescription, ask whether another location or another strength is available. Then call your prescriber before you run out.
  • Keep naloxone (Narcan) in the house. The CDC says it is sold over the counter, won't harm someone who has not taken opioids, and more than one dose may be needed with fentanyl.
  • Never take a pill that did not come from a pharmacy.
  • If opioid use has gotten out of control, get treatment now. Don't wait for the next refill problem. Our area has lost neighbors to overdose, and I track the county overdose numbers for Northwest Arkansas.

How I can help

I am a physician in Fayetteville, and I treat opioid use disorder with buprenorphine. You see me, the same doctor, at every visit. A scheduled visit is $200, and I don't bill insurance. Your records are private under the federal rule called 42 CFR Part 2. My office does not do inpatient detox, and I don't dispense methadone.

I answer my own phone, day or night. If you aren't sure whether this is the right fit, call and ask. You can also read what the first visit looks like before you decide. If you are ready, call me at 479-856-1505 to make an appointment.

If someone is very hard to wake, breathing slowly, or has blue or gray lips, call 911 now and give naloxone if you have it. If you or someone you love is thinking about suicide or is in emotional crisis, call or text 988, the Suicide & Crisis Lifeline.

Questions people ask

Is the DEA cutting opioid production in 2027?

Yes, slightly. In its proposed 2027 quotas, published Nov. 10, 2026, the DEA lowered oxycodone (for sale) by about 0.8 percent and hydrocodone (for sale) by about 0.5 percent compared with 2026. Morphine is unchanged and hydromorphone is higher. Public comments are open until Dec. 10, 2026.

Why is the DEA lowering opioid quotas?

The DEA says the FDA predicts medical use of Schedule II opioids will decline an average of 9.68 percent in 2027. The DEA is also required to factor in estimates of diversion, meaning medicine that ends up outside legitimate use.

Will there be an oxycodone or hydrocodone shortage in Arkansas?

No one can promise what a given pharmacy will stock. The national cuts proposed for 2027 are under one percent, and the DEA says it monitors drug shortages. If your pharmacy cannot fill a prescription, ask about another location and call your prescriber before you run out.

Does the opioid quota affect Suboxone?

No. This quota covers Schedule I and II drugs. Buprenorphine, the main medicine in Suboxone, is listed by the DEA as a Schedule III drug.

What should I do if my pain medicine is stopped suddenly?

Do not buy pills off the street. The FDA has warned that suddenly stopping opioids in someone who is physically dependent can cause serious withdrawal, uncontrolled pain, distress and suicide, and the DEA warns that fake pills often contain fentanyl. Ask your prescriber for a gradual plan.

Can Dr. Tomlinson prescribe pain medicine?

No. Dr. Tomlinson treats opioid use disorder with buprenorphine (Suboxone). If opioid use has gotten out of control, call 479-856-1505; he answers his own phone.

Sources

  1. Drug Enforcement Administration, “Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances … for 2027,” Federal Register (Nov. 10, 2026) — https://www.federalregister.gov/documents/2026/11/10/2026-22843/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of
  2. Drug Enforcement Administration, “Established Aggregate Production Quotas for Schedule I and II Controlled Substances … for 2026,” Federal Register (Jan. 5, 2026) — https://www.federalregister.gov/d/2025-24277
  3. Drug Enforcement Administration, “Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale),” Federal Register (Nov. 10, 2026) — https://www.federalregister.gov/documents/2026/11/10/2026-22842/adjustment-to-the-2026-aggregate-production-quota-for-dl-amphetamine-d-amphetamine-for-sale
  4. Pain News Network, “DEA Plans Minor Cuts in Opioid Supply in 2027” (Nov. 14, 2026) — https://www.painnewsnetwork.org/stories/2026/11/14/dea-plans-minor-cuts-in-opioid-supply-in-2027
  5. U.S. Food and Drug Administration, “FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering” (April 9, 2019) — https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes-guide
  6. Dowell D, et al. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022.” MMWR Recommendations and Reports 2022;71(3) — https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
  7. DEA Diversion Control Division, “Controlled Substances – Alphabetical Order” (buprenorphine, Schedule III) — https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
  8. Drug Enforcement Administration, “One Pill Can Kill” — https://www.dea.gov/onepill
  9. Centers for Disease Control and Prevention, “Lifesaving Naloxone” — https://www.cdc.gov/stop-overdose/caring/naloxone.html
  10. Centers for Disease Control and Prevention, “Treating Opioid Use Disorder” — https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html
  11. National Institute on Drug Abuse, “Medications for Opioid Use Disorder” — https://nida.nih.gov/research-topics/medications-opioid-use-disorder
Call 479-856-1505 Call me instead